Synthesis and characterization of novel 99mTc-DGC nano-complexes for improvement of heart diagnostic

Ardestani, Mehdi Shafiee; Bitarafan-Rajabi, Ahmad; Mohammadzadeh, Pardis; Mortazavi‐Derazkola, Sobhan; Sabzevari, Omid; Darbandi-Azar, Amir; Kazemi, Sohrab; Hosseini, Seyedeh Rozhin; Ghoreishi, Seyedeh Masoumeh

doi:10.1016/j.bioorg.2020.103572

Cited by 45 publications

(15 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28A). Once again, the binding of [ 99m Tc]TcO 4 after SnCl 2 reduction has been described by several groups, [457][458][459][460][461] allowing high RCYs and serum stability. Interestingly, Tassano et al found the [ 99m Tc][Tc(CO) 3 ] + core could bind to PAMAM dendrimers with ca.…”

Section: Radiolabelling Of Organic Nanomaterialsmentioning

confidence: 99%

Radiolabelling of nanomaterials for medical imaging and therapy

2021

View full text Add to dashboard Cite

show abstract

Section: Radiolabelling Of Organic Nanomaterialsmentioning

confidence: 99%

Radiolabelling of nanomaterials for medical imaging and therapy

2021

View full text Add to dashboard Cite

show abstract

“…After incubation with 99m Tc, the complex was also used for SPECT scintigraphy of normal and infarcted rabbits. It was shown in particular that this compound is able to accurately diagnose myocardial infarctions at early stages [103]. For increasing the detection of the cardiac ischemic region, a specific peptide was elaborated and grafted to the ALGD, with no additional functions (Figure 25D).…”

Section: Technetium Complexes Of Other Dendrimersmentioning

confidence: 99%

Dendritic metal complexes for bioimaging. Recent advances

Caminade

Hameau

Turrin

et al. 2021

Coordination Chemistry Reviews

View full text Add to dashboard Cite

Dendrimers are hyperbranched macromolecules, having a large number of terminal functions, easily accessible and modifiable to afford the desired properties. Metal complexes of dendrimers are frequently used as catalysts in diverse reactions, but they can be used also as innovative biological tools. This review focusses on the recent advances (last 10 years) of dendritic metal complexes used for bioimaging, essentially in vivo. Three main domains will be covered. The first one concerns luminescent complexes for optical imaging (OI). The second one is the largest one; it concerns magnetic resonance imaging (MRI) contrast agents, mostly based on gadolinium complexes. The third and last domain concerns radioactive dendrimer complexes for single photon emission computed tomography (SPECT), and also for positron emission tomography (PET). Two main radionucleides are used in this context, technetium ( 99m Tc) and indium ( 111 In). Two types of ligands are generally used for all these complexes in the two last domains, diethylenetriaminepentaacetic acid (DTPA), and a cyclic analogue, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), and some of their derivatives. These complexes have been used in many cases for in vivo imaging of cancerous tumors in mice or rats.

show abstract

“…Development of research on nanomaterials for medical applications has been carried out in the last three decades; most researches concentrated on their safety and toxicity on human cell and tissue function [ 8 , 9 , 10 , 11 ]. However, the biomedical applications of GO, such as anticancer drug delivery, developed quickly over the past 15 years.…”

Section: Introductionmentioning

confidence: 99%

Graphene oxide‐ellagic acid nanocomposite as effective anticancer and antimicrobial agent

Hussein‐Al‐Ali

Abudoleh

Hussein

et al. 2021

IET Nanobiotechnology

View full text Add to dashboard Cite

In this study, ellagic acid (ELA), a skin anticancer drug, is capped on the surface(s) of functionalised graphene oxide (GO) nano-sheets through electrostatic and π-π staking interactions. The prepared ELA-GO nanocomposite have been thoroughly characterised by using eight techniques: Fourier-transform infrared spectroscopy (FTIR), zeta potential, X-ray diffraction (XRD), thermogravimetric analysis (TGA), Raman spectroscopy, atomic force microscopy (AFM) topographic imaging, transmission electron microscopy (TEM), and surface morphology via scanning electron microscopy (SEM). Furthermore, ELA drug loading and release behaviours from ELA-GO nanocomposite were studied. The ELA-GO nanocomposite has a uniform size distribution averaging 88 nm and high drug loading capacity of 30 wt.%. The in vitro drug release behaviour of ELA from the nanocomposite was investigated by UV-Vis spectrometry at a wavelength of λ max 257 nm. The data confirmed prolonged ELA release over 5000 min at physiological pH (7.4). Finally, the IC 50 of this ELA-GO nanocomposite was found to be 6.16 µg/ml against B16 cell line; ELA and GO did not show any cytotoxic effects up to 50 µg/ml on the same cell lines. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

Synthesis and characterization of novel 99mTc-DGC nano-complexes for improvement of heart diagnostic

Cited by 45 publications

References 33 publications

Radiolabelling of nanomaterials for medical imaging and therapy

Radiolabelling of nanomaterials for medical imaging and therapy

Dendritic metal complexes for bioimaging. Recent advances

Graphene oxide‐ellagic acid nanocomposite as effective anticancer and antimicrobial agent

Contact Info

Product

Resources

About